{"id":32915,"date":"2025-04-08T09:35:34","date_gmt":"2025-04-08T13:35:34","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=32915"},"modified":"2026-09-27T14:23:16","modified_gmt":"2026-09-27T18:23:16","slug":"valuation-of-pharma-companies-5-key-considerations-2","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/valuation-of-pharma-companies-5-key-considerations-2\/","title":{"rendered":"Pharma Valuation, Priced Correctly: The rNPV Math Behind Every Biotech Deal in 2026"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

On November 8, 2025, Pfizer agreed to pay up to $10 billion for Metsera, a clinical-stage obesity biotech with no approved product, after a bidding war with Novo Nordisk pushed the price 159% above Metsera’s pre-deal share price [12]. The structure told the real story: $65.60 per share in guaranteed cash, plus a contingent value right worth up to $20.65 per share, payable only if specific clinical and regulatory milestones land [12]. Two buyers, looking at the same clinical data, priced roughly a third of the deal as pure uncertainty. That gap between the guaranteed and the contingent is what pharmaceutical valuation is actually about.<\/p>\n\n\n\n

Generic financial models are not built for this. A discounted cash flow that assumes a company simply grows into perpetuity breaks the moment a molecule’s economic life is fixed by a patent clock and a regulatory exclusivity date. This guide sets out how professionals actually build these numbers in 2026: the risk-adjusted net present value (rNPV) framework that dominates clinical-stage valuation, the patient-based models used to forecast revenue, the discount-rate mechanics that change as a drug de-risks, and the patent-cliff math that ultimately caps the whole exercise.<\/p>\n\n\n\n

1. Matching the Valuation Method to the Stage of the Asset<\/strong><\/h2>\n\n\n\n

There is no universal formula for pricing a drug company. The right method is a function of how much clinical uncertainty remains.<\/p>\n\n\n\n

Preclinical and Discovery-Stage Assets<\/strong><\/h3>\n\n\n\n

A standard DCF is close to meaningless 10 to 15 years before any cash flow exists. Analysts instead lean on comparable transactions \u2014 benchmarking upfront payments and deal structures against similar early assets \u2014 and the Venture Capital Method, which works backward from a targeted exit return to today’s implied value.<\/p>\n\n\n\n

Clinical-Stage Assets (Phase I Through Phase III)<\/strong><\/h3>\n\n\n\n

This is rNPV territory. The model explicitly multiplies each future cash flow by the cumulative probability that the program survives to that point, which lets analysts use a discount rate tied to the cost of capital rather than an arbitrary “risk premium” bolted onto the rate itself.<\/p>\n\n\n\n

Commercial-Stage Companies<\/strong><\/h3>\n\n\n\n

Once a drug is approved and selling, valuation converges on conventional corporate finance: standard DCF, EV\/Revenue, and P\/E multiples. The one persistent complication is the patent cliff, which turns the usual perpetuity-growth terminal value into a cliff-edge problem (Section 7).<\/p>\n\n\n\n

Why One DCF Cannot Span the Whole Lifecycle<\/strong><\/h3>\n\n\n\n

A 60% discount rate applied to a preclinical asset is not describing the cost of capital \u2014 it is trying to make a single number do the work of both technical risk and time-value risk simultaneously. That conflation is the single most common valuation error in the sector, and it resurfaces throughout this guide.<\/p>\n\n\n\n

2. Risk-Adjusted NPV: The Core Engine of Clinical-Stage Valuation<\/strong><\/h2>\n\n\n\n

rNPV sums the present value of every future cash flow, each one weighted by the cumulative probability that the asset reaches that point. Costs are only real if the program is still alive; revenue is only real if the program has been approved.<\/p>\n\n\n\n

The Formula and Its Two Phases<\/strong><\/h3>\n\n\n\n

The model splits cleanly into an investment phase \u2014 Phase I, II, and III costs, each incurred only if the prior phase succeeded \u2014 and a commercial phase, where revenue and operating costs are weighted by the cumulative likelihood of approval (LOA).<\/p>\n\n\n\n

Phase Transition Probabilities: The Benchmark Table<\/strong><\/h3>\n\n\n\n

The reliability of an rNPV model depends entirely on its probability-of-success inputs. Historic transition-probability benchmarks (Phase I ~60-65%, Phase II ~35-40%, Phase III ~60-65%, submission ~90%) remain the starting point most analysts use, though 2026 data shows the picture is beginning to bifurcate by how the program was generated.<\/p>\n\n\n\n

Development Phase<\/th>Typical Transition Probability<\/th>Primary Risk<\/th>2026 Update<\/th><\/tr><\/thead>
Phase I<\/td>60% \u2013 65% (industry average)<\/td>Safety and pharmacokinetics<\/td>AI-enabled emerging biopharma programs showed a 75% Phase I success rate over the most recent three-year window [1]<\/td><\/tr>
Phase II<\/td>35% \u2013 40%<\/td>First proof of efficacy \u2014 the highest-attrition stage<\/td>Phase II success rates for AI-enabled programs are tracking in line with non-AI-enabled peers, so the AI benefit is not simply pulling forward doomed programs [1]<\/td><\/tr>
Phase III<\/td>60% \u2013 65%<\/td>Large-scale efficacy and safety<\/td>Median end-to-end clinical development time reached 10 years in 2025, up from prior years, as enrollment and trial duration lengthened [2]<\/td><\/tr>
NDA\/BLA Submission<\/td>~90%<\/td>Manufacturing, labeling, inspection<\/td>Review-stage risk is largely administrative rather than scientific<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Analysis: The 10-year median timeline reported for 2025 is a documented industry figure [2]; the implication that this pushes revenue recognition further into the discounting period, and therefore compresses NPV, is our calculation based on that figure, not a reported statistic.<\/em><\/p>\n\n\n\n

Therapeutic-Area Adjustments to Probability of Success<\/strong><\/h3>\n\n\n\n

A generic industry-average PoS misprices almost every real asset, because attrition is not evenly distributed across disease areas.<\/p>\n\n\n\n

Oncology<\/h4>\n\n\n\n

Overall oncology success rates run lower than the industry average, driven by the biological complexity of cancer, though biomarker-driven precision-oncology trials outperform unselected “all-comers” designs.<\/p>\n\n\n\n

CNS and Neurodegeneration<\/h4>\n\n\n\n

Central nervous system programs \u2014 particularly Alzheimer’s and Parkinson’s \u2014 carry the highest technical risk in the industry, largely because subjective endpoints and poor animal-to-human translation drive repeated late-stage failures.<\/p>\n\n\n\n

Rare Disease and Orphan Drugs<\/h4>\n\n\n\n

Orphan programs often show materially higher probability of success, helped by well-characterized, often monogenic patient populations and greater regulatory flexibility on endpoints and trial size.<\/p>\n\n\n\n

Immunology and Metabolic Disease<\/h4>\n\n\n\n

Metabolic disease \u2014 obesity and GLP-1 programs in particular \u2014 and immunology have shown improving technical success rates recently, though the Phase III trials required in these categories are large and expensive enough that financial risk stays high even where clinical risk has fallen.<\/p>\n\n\n\n

The Double-Counting Error<\/strong><\/h3>\n\n\n\n

A common and serious mistake is applying both a punitive discount rate (to “price in risk”) and a probability-of-success haircut to the same cash flows. Clinical failure is asset-specific, uncorrelated with the broader market, and belongs in the probability adjustment \u2014 not in the discount rate. Doing both understates value, sometimes by a large margin.<\/p>\n\n\n\n

3. Modeling Development Costs and Timelines<\/strong><\/h2>\n\n\n\n

Cost Drivers by Trial Type<\/strong><\/h3>\n\n\n\n

Cost scales with patient count, site count, and protocol complexity. A small Phase I oncology study can run $5\u201315 million; a 10,000-patient Phase III cardiovascular outcomes trial can exceed $500 million to $1 billion.<\/p>\n\n\n\n

R&D Inflation and the Logistics Cost Curve<\/strong><\/h3>\n\n\n\n

Trial complexity \u2014 procedures per patient visit \u2014 has flattened recently even as logistical costs (additional sites, additional countries, trial technology) keep rising, which is why models built on a flat 2% CPI-based inflation assumption for R&D costs consistently understate true program spend.<\/p>\n\n\n\n

Timeline Slippage and Its Compounding Effect on NPV<\/strong><\/h3>\n\n\n\n

Because the discount factor compounds over time, a delay does not just push revenue back \u2014 it shrinks its present value disproportionately the further out it lands. A program that slips from a 7-year to a 9-year time-to-launch does not lose two years of value; at a 12% discount rate, it loses roughly 20% more value than the delay alone would suggest, because every dollar of eventual revenue is now being discounted for two additional years. (This is our calculation, illustrating the mechanism \u2014 not a reported industry statistic.)<\/em><\/p>\n\n\n\n

4. Revenue Forecasting: The Patient-Based Model<\/strong><\/h2>\n\n\n\n

Top-down forecasting \u2014 “we’ll capture 5% of a $10 billion market” \u2014 is treated as a red flag by institutional analysts. The credible alternative builds the forecast bottom-up from epidemiology.<\/p>\n\n\n\n

The Epidemiological Cascade<\/strong><\/h3>\n\n\n\n

The funnel runs from total prevalence or incidence, through diagnosis rate, through treatment rate, down to the specific label population the drug is approved to treat. A second-line indication addresses a fraction of the market a first-line approval would reach, and collapsing that distinction is one of the more common forecasting errors.<\/p>\n\n\n\n

Adoption Curves and the Bass Diffusion Model<\/strong><\/h3>\n\n\n\n

Drug uptake follows an S-curve rather than a straight line. The Bass Diffusion Model formalizes this with two coefficients: an “innovation” coefficient capturing the effect of marketing and launch visibility, and an “imitation” coefficient capturing word-of-mouth, publication, and key-opinion-leader influence. First-in-class drugs typically show a higher innovation coefficient; me-too entrants lean more heavily on imitation.<\/p>\n\n\n\n

Peak Sales Timing and the Physician-Survey Haircut<\/strong><\/h3>\n\n\n\n

Analysts typically model peak sales as landing 6 to 10 years after launch, and routinely discount stated “intent to prescribe” data from physician surveys by 30\u201350% to correct for optimism bias in primary market research.<\/p>\n\n\n\n

Gross-to-Net Pricing and the IRA’s Structural Divergence<\/strong><\/h3>\n\n\n\n

Net price \u2014 after rebates, chargebacks, 340B discounts, and statutory Medicaid\/Medicare rebates \u2014 is the only price that belongs in a valuation model. In competitive drug classes, gross-to-net discounts can exceed 50%; in protected orphan categories they are often 10\u201315%.<\/p>\n\n\n\n

The Inflation Reduction Act (IRA) has made this modeling meaningfully more complex since 2022. Under the Medicare Drug Price Negotiation Program, small-molecule drugs become eligible for negotiated pricing nine years after approval, while biologics get a 13-year runway \u2014 a gap widely referred to in the industry as the “pill penalty,” because it pushes sponsors toward biologics or later small-molecule optimization to maximize the negotiation-free window.<\/p>\n\n\n\n

Negotiation Cycle<\/th>Number of Drugs<\/th>Negotiation Period<\/th>Prices Effective<\/th>Estimated Savings<\/th><\/tr><\/thead>
Cycle 1 (IPAY 2026)<\/td>10 Part D drugs<\/td>Concluded 2024<\/td>January 1, 2026<\/td>Projected ~$6 billion annually [29]<\/td><\/tr>
Cycle 2 (IPAY 2027)<\/td>15 Part D drugs, incl. semaglutide products (Ozempic, Wegovy, Rybelsus)<\/td>Ended November 1, 2025<\/td>January 1, 2027<\/td>Projected $8.5\u2013$12 billion annually [21][30]; semaglutide products negotiated to roughly 71% off list, near $274 for a 30-day-equivalent supply [29]<\/td><\/tr>
Cycle 3 (IPAY 2028)<\/td>Up to 15 Part D and Part B drugs<\/td>2026\u20132027<\/td>January 1, 2028<\/td>All 15 selected manufacturers agreed to participate as of the March 2026 CMS announcement [26]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

By 2029, up to 20 additional drugs per year become eligible, and Part B products join the program for the first time starting with the 2028 cycle \u2014 a scope expansion that valuation models for any single-source biologic or small molecule approaching nine (small molecule) or thirteen (biologic) years post-approval now need to build in explicitly as a step-down, rather than model as smooth long-term price growth.<\/p>\n\n\n\n

4. Discount Rates: Why the Number Changes as the Molecule Matures<\/strong><\/h2>\n\n\n\n

The Step-Down Discount Rate Framework<\/strong><\/h3>\n\n\n\n

Because a biotech’s risk profile changes qualitatively as it advances, practitioners step the discount rate down stage by stage rather than holding one WACC constant across the company’s life.<\/p>\n\n\n\n

Development Stage<\/th>Typical Discount Rate<\/th>Rationale<\/th><\/tr><\/thead>
Preclinical \/ Discovery<\/td>20% \u2013 25%+<\/td>Pre-revenue, equity-funded, existential binary risk<\/td><\/tr>
Early Clinical (Phase I\/II)<\/td>15% \u2013 20%<\/td>Commercial viability still unproven; financing risk remains high<\/td><\/tr>
Late Clinical (Phase III)<\/td>10% \u2013 15%<\/td>Asset is substantially de-risked; company begins resembling a commercial entity<\/td><\/tr>
Commercial \/ Mature<\/td>7% \u2013 9%<\/td>Stable cash flow, debt-market access, beta correlates with the broader healthcare sector<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Systematic vs. Non-Systematic Risk<\/strong><\/h3>\n\n\n\n

Under CAPM logic, a discount rate should only reflect systematic risk \u2014 the risk that cannot be diversified away. Whether a molecule binds its target has nothing to do with interest rates or equity-market cycles, so that risk belongs in the cash-flow probability adjustment, not the discount rate. This is the same double-counting trap flagged in Section 2, applied at the portfolio level.<\/p>\n\n\n\n

VC Hurdle Rates vs. Cost of Capital<\/strong><\/h3>\n\n\n\n

Venture investors often apply a 40\u201360% hurdle rate to unadjusted cash flows. That figure is a target IRR compensating for portfolio-wide illiquidity and mortality, not a cost-of-capital estimate, and it is a poor substitute for rNPV when the goal is a defensible asset-level valuation rather than a fund-level return target.<\/p>\n\n\n\n

5. The Patent Cliff: Modeling the Terminal Value Problem<\/strong><\/h2>\n\n\n\n

Most industries can model a terminal value as a perpetuity growing at 2\u20133% a year. Pharmaceutical assets cannot: their economic life ends at a specific, calculable date set by the later of patent expiry or regulatory exclusivity \u2014 the loss of exclusivity (LOE) date.<\/p>\n\n\n\n

Regulatory Exclusivity Periods<\/strong><\/h3>\n\n\n\n
Exclusivity Type<\/th>Duration<\/th>Statutory Basis<\/th><\/tr><\/thead>
New Chemical Entity (small molecule)<\/td>5 years<\/td>21 U.S.C. \u00a7 355(c)(3)(E) [66]<\/td><\/tr>
Biologics (BPCIA)<\/td>12 years<\/td>42 U.S.C. \u00a7 262(k)(7) [66]<\/td><\/tr>
Orphan Drug Designation<\/td>7 years (US)<\/td>Orphan Drug Act [66]<\/td><\/tr>
Pediatric Exclusivity<\/td>+6 months, stacked on other exclusivity<\/td>21 U.S.C. \u00a7 355a [66]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Patent Term Extension Mechanics<\/strong><\/h3>\n\n\n\n

Under the Hatch-Waxman Act, codified at 35 U.S.C. \u00a7 156, a patent owner can recover part of the term lost to clinical testing and FDA review \u2014 calculated as half the testing-phase time plus all of the review-phase time [61]. The extension is capped at 5 years, and the combined post-approval patent life cannot exceed 14 years from approval, regardless of how much term was technically lost [61] [64]. Because the calculation only ever restores time already spent, and because it caps out well short of what a full 20-year term would provide from filing, “effective” patent life for a drug that spent a decade in development is routinely 10\u201314 years rather than 20.<\/p>\n\n\n\n

Erosion Curves Differ Sharply by Modality<\/strong><\/h3>\n\n\n\n

Small-molecule generics erode fast: automatic pharmacy-level substitution laws typically drive an 80\u201390% price collapse within 12 months of generic entry. Biosimilars erode more slowly, both because manufacturing complexity limits the number of entrants and because interchangeability designations \u2014 which permit pharmacy-level substitution without a new prescription \u2014 are not automatic.<\/p>\n\n\n\n

Humira is the clearest documented case study of biologic erosion. AbbVie’s estimated net price per Humira prescription fell more than 50% between 2022 and 2024 [59]. US revenue fell 39.9% year-over-year in the first quarter of 2024 alone, from $2.948 billion to $1.771 billion [55], and reported first-quarter US sales were down roughly 40% year-over-year following CVS Health’s removal of Humira from its national commercial formularies effective April 1, 2024 [57]. Formulary access for the biosimilars themselves kept widening afterward: by the 2025 plan year, 96% of Medicare Part D Prescription Drug Plans and 88% of Medicare Advantage Prescription Drug plans covered at least one of the ten available Humira biosimilars [53].<\/p>\n\n\n\n

\n

IQVIA-sourced industry estimates cited in sell-side research put US biologics losing patent protection between 2025 and 2034 at roughly 118 products, corresponding to approximately $232 billion in exposed sales \u2014 a scale competitors such as Sandoz are explicitly building multi-decade biosimilar strategies around [54].<\/p>\n<\/blockquote>\n\n\n\n

The 2025\u20132030 Super-Cliff, Quantified<\/strong><\/h3>\n\n\n\n

Estimates of the current patent cliff’s total size vary by methodology and time window, which is itself a useful data point about how sensitive these numbers are to what counts as “at risk”:<\/p>\n\n\n\n

    \n
  • $236 billion in global revenue at risk from roughly 70 high-revenue products between 2025 and 2030, per widely cited industry tallies [4][19]<\/li>\n\n\n\n
  • Approximately $180 billion by 2030 per PitchBook estimates, with some estimates running higher, and a total as high as $400 billion by 2033 in STAT’s broader estimate [14]<\/li>\n\n\n\n
  • More than $230 billion in US-market revenue alone between 2025 and 2030, per Drug Discovery News reporting [15]<\/li>\n\n\n\n
  • Nearly 200 drugs losing patent or exclusivity protection industry-wide between 2025 and 2030, roughly 70 of them individually generating over $1 billion a year [18]<\/li>\n<\/ul>\n\n\n\n

    Analysis: the spread across these figures ($180B to $400B) reflects differences in time window (2030 vs. 2033), geography (global vs. US), and whether the count includes mid-size products alongside blockbusters \u2014 not disagreement about which drugs are expiring.<\/em><\/p>\n\n\n\n

    Company-Level Exposure<\/strong><\/h3>\n\n\n\n
    Company<\/th>Documented At-Risk Revenue \/ Exposure<\/th>Key Products and Timing<\/th><\/tr><\/thead>
    Bristol-Myers Squibb<\/td>~$22 billion at-risk revenue against a ~$38 billion growth gap \u2014 the largest growth gap among large-cap peers [17]; up to 47% of revenue characterized as at risk by 2030 in some estimates [17]<\/td>Eliquis and other core franchise products facing loss of exclusivity within the 2025\u20132030 window [14]<\/td><\/tr>
    Merck<\/td>Januvia\/Janumet loss of exclusivity in 2026, following settlements with 25 generic manufacturers permitting launch in May 2026 [15]<\/td>Keytruda, the world’s best-selling drug, expected to lose patent protection in 2028 \u2014 described by analysts as a far larger disruption than the 2026 diabetes-franchise erosion [15]<\/td><\/tr>
    Pfizer<\/td>Prevnar loses exclusivity in 2026; combined with Ibrance (2027) and Xtandi (2027), more than $15 billion in at-risk revenue [17]<\/td>Diversifying into new modalities including the 2025 Metsera acquisition (Section 10) [12]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Industry-wide, eight of the thirteen largest pharmaceutical companies by market value \u2014 together representing an estimated 55% of the sector’s global market capitalization \u2014 could see 30% or more of current revenue exposed by 2026, with per-company losses estimated to range from roughly $6 billion to $38 billion [17].<\/p>\n\n\n\n

    6. Real Options Valuation: Pricing Managerial Flexibility<\/strong><\/h2>\n\n\n\n

    rNPV assumes a single, linear development path. In reality, management holds a set of options at every decision point: continue, abandon, expand into a new indication, or out-license. Real Options Valuation (ROV) prices that flexibility using option-pricing theory.<\/p>\n\n\n\n

    Binomial Lattices Over Black-Scholes<\/strong><\/h3>\n\n\n\n

    Black-Scholes assumes continuous time and continuous trading, which does not describe clinical development. Binomial lattices instead map directly onto the discrete go\/no-go decision points that separate Phase I from Phase II from Phase III, with each node valued as the greater of continuing (net of the next phase’s cost) or abandoning for zero.<\/p>\n\n\n\n

    Why Higher Volatility Increases Value Here \u2014 and Only Here<\/strong><\/h3>\n\n\n\n

    In a standard DCF, more uncertainty means a higher discount rate and a lower value. In real options, the opposite holds: since the downside is capped at the R&D cost of abandoning the program, higher volatility mainly raises the odds of an outsized “blockbuster” upside, which increases the value of holding the option. Biotech assets commonly show modeled volatilities of 40\u201360% or more.<\/p>\n\n\n\n

    When ROV Is the Better Tool Than rNPV<\/strong><\/h3>\n\n\n\n

    ROV tends to produce a higher valuation than rNPV precisely because it captures the right-tail blockbuster scenario that a straight probability-weighted average tends to smooth away \u2014 which is why it is used most often for assets with a genuinely bimodal outcome distribution, such as CNS programs (Section 11).<\/p>\n\n\n\n

    7. Comparable Company and Deal Analysis<\/strong><\/h2>\n\n\n\n

    Multiples for Development-Stage Companies<\/strong><\/h3>\n\n\n\n

    With no earnings to anchor a P\/E multiple, analysts instead use EV\/R&D spend (a proxy for research productivity) and EV\/Cash. In downturns, many biotechs trade below 1.0x cash, implying the market views continued R&D spending as value-destructive; a healthy early-stage biotech in a stronger market typically trades at 2x\u20134x cash.<\/p>\n\n\n\n

    Multiples for Commercial-Stage Companies<\/strong><\/h3>\n\n\n\n

    Established pharma typically trades at 4x\u20136x EV\/Revenue, with high-growth biotechs launching a first blockbuster reaching 8x\u201310x. P\/E multiples for mature pharma tend to run 15x\u201320x \u2014 compressed relative to technology or consumer staples because of the permanent overhang of the patent cliff on terminal value.<\/p>\n\n\n\n

    2026 Deal Comparables<\/strong><\/h3>\n\n\n\n

    Real transaction data is the most defensible comparable, and 2026 has produced an unusually rich set of data points. H1 2026 alone produced roughly $149 billion in disclosed biotech M&A value across 49 control transactions, with eleven deals of $5 billion or more accounting for roughly two-thirds of total value [35].<\/p>\n\n\n\n

    Deal<\/th>Value<\/th>Structure<\/th>Date<\/th><\/tr><\/thead>
    Sun Pharma \/ Organon<\/td>~$11.75 billion<\/td>All-cash, $14 per share [38]<\/td>Announced April 26, 2026 [38]<\/td><\/tr>
    CVC\/GBL \/ Recordati<\/td>~$12.4 billion<\/td>Take-private [35]<\/td>H1 2026 [35]<\/td><\/tr>
    Gilead \/ Tubulis<\/td>Up to $5 billion<\/td>$3.15 billion upfront + up to $1.85 billion in milestones [38]<\/td>April 2026 [38]<\/td><\/tr>
    Novo Nordisk \/ Akero<\/td>$5.2 billion<\/td>Cash acquisition following positive Phase III MASH data [32]<\/td>October 2025 [32]<\/td><\/tr>
    Pfizer \/ Metsera<\/td>Up to $10 billion<\/td>$65.60\/share cash + CVR up to $20.65\/share [45]<\/td>Closed November 13, 2025 [45]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

    Eli Lilly was the most active acquirer of H1 2026 by deal count, signing eleven agreements worth an estimated $25 billion combined, spanning modalities from oral inflammation assets to in vivo cell therapy [35].<\/p>\n\n\n\n

    8. Deal Structuring: Contingent Value Rights in Practice<\/strong><\/h2>\n\n\n\n

    Anatomy of a Biobucks Deal<\/strong><\/h3>\n\n\n\n

    A typical structure separates a guaranteed upfront cash payment, which sets the valuation floor, from milestone payments \u2014 regulatory (e.g., a fixed per-share payment on FDA approval) or commercial (e.g., a payment triggered once net sales cross a stated threshold).<\/p>\n\n\n\n

    Valuing the CVR<\/strong><\/h3>\n\n\n\n

    A CVR is not worth its face value; it must be probability-weighted and discounted like any other contingent cash flow. Public CVRs frequently trade at a steep discount to their theoretical value \u2014 sometimes toward zero \u2014 because the market prices in the risk that the acquirer, once in control of the asset, has limited incentive to accelerate development toward the milestone.<\/p>\n\n\n\n

    Case Study: The Pfizer\u2013Metsera CVR<\/strong><\/h3>\n\n\n\n

    The Metsera deal is a clean, fully disclosed example of how a real bidding war splits guaranteed and contingent value. Pfizer’s winning bid paid $65.60 per share in cash immediately, with up to $20.65 per share contingent on clinical and regulatory milestones \u2014 meaning roughly 24% of the deal’s maximum headline value was structured as a CVR rather than guaranteed cash [45]. Novo Nordisk’s final, unsuccessful counter-offer used a similar split: $62.20 in guaranteed cash plus a $24 CVR [49]. Both bidders, independently, priced the contingent portion of an obesity-drug asset at roughly a quarter to a third of total deal value \u2014 a useful anchor for analysts building CVR assumptions into comparable deals in the same therapeutic area.<\/p>\n\n\n\n

    9. Sector-Specific Valuation Nuances<\/strong><\/h2>\n\n\n\n

    Oncology: The Line-of-Therapy Premium<\/strong><\/h3>\n\n\n\n

    A first-line oncology approval \u2014 treating patients at initial diagnosis \u2014 commands a materially higher valuation than a third-line “salvage therapy” approval, driven by both a larger patient pool and longer treatment duration. The shift toward tumor-agnostic approvals, granted on genetic markers like MSI-H rather than organ site, has also forced a shift from organ-based to mutation-based epidemiology modeling.<\/p>\n\n\n\n

    Gene and Cell Therapy: The One-and-Done Model<\/strong><\/h3>\n\n\n\n

    Chronic therapies generate an annuity-style revenue stream; a curative gene therapy instead generates a lump of revenue that quickly clears the existing prevalence pool and then depends entirely on new incidence. This dynamic is what justifies price points in the low millions of dollars per dose, and it requires valuation models sensitive to payer adoption assumptions and novel payment structures such as multi-year annuity payments contingent on continued efficacy.<\/p>\n\n\n\n

    CNS: The Barbell Distribution<\/strong><\/h3>\n\n\n\n

    A disease-modifying Alzheimer’s therapy addresses a total addressable market exceeding $50 billion, but historical probability of success in the category is low enough that a realistic value distribution looks like a barbell \u2014 clustered near zero and near tens of billions of dollars, with little mass in between. That is precisely the shape of outcome real options valuation is built to price (Section 6).<\/p>\n\n\n\n

    10. The 2026 Macro Backdrop<\/strong><\/h2>\n\n\n\n

    Capital Markets and Rate Sensitivity<\/strong><\/h3>\n\n\n\n

    Because biotech cash flows sit far in the future, their present value is unusually sensitive to the discount rate: a one-percentage-point drop in the assumed rate can raise the present value of a preclinical asset by 20\u201330%, which is part of why financing conditions have such an outsized effect on biotech valuations relative to other sectors.<\/p>\n\n\n\n

    FTC Scrutiny and Deal-Break Risk<\/strong><\/h3>\n\n\n\n

    Antitrust review has become a real, quantifiable deal variable rather than a formality. The Pfizer-Metsera contest is itself a live example: Novo Nordisk’s competing bid was ultimately abandoned after the FTC flagged potential competition concerns with that specific deal structure, while Pfizer’s bid had already cleared FTC review \u2014 a difference in regulatory risk that Metsera’s board explicitly cited in choosing the lower nominal per-share offer [45][43]. Analysts increasingly build an explicit probability-of-close term into M&A arbitrage valuations for exactly this reason.<\/p>\n\n\n\n

    AI-Enabled R&D: Early, Real Signal<\/strong><\/h3>\n\n\n\n

    The IQVIA Institute’s Global R&D Trends 2026 report is the first major industry dataset to show a measurable, rather than anecdotal, success-rate benefit tied to AI-enabled discovery: a 75% three-year Phase I success rate for AI-enabled programs at emerging biopharma companies, with Phase II rates for the same cohort holding steady rather than declining \u2014 evidence, the report notes, against the concern that AI is simply pulling weaker programs into Phase I rather than genuinely de-risking them [1]. This remains a young, narrow dataset (one cohort, one three-year window), so it belongs in a valuation model as a modest upward adjustment to Phase I PoS for genuinely AI-native programs, not as a blanket re-rating of industry-wide success rates.<\/p>\n\n\n\n

    Methodology<\/strong><\/h2>\n\n\n\n

    Figures and dates in this article are drawn from named primary and secondary sources current as of September 2026, cited inline. Deal values reflect headline totals as publicly disclosed by the companies involved, including contingent milestone payments where structured as CVRs; actual realized value may differ from headline value depending on whether milestones are met. Patent-cliff aggregate figures ($180B\u2013$400B, 2025\u20132030\/2033) come from multiple independent industry sources using different time windows and geographic scopes, noted explicitly where cited, rather than reconciled into one number. Illustrative calculations (the NPV-compounding example in Section 3, the CVR-share-of-deal-value calculation in Section 8) are marked as such and are not attributed to any external source.<\/p>\n\n\n\n

    Definitions<\/strong><\/h2>\n\n\n\n
      \n
    • rNPV (Risk-Adjusted Net Present Value):<\/strong> A DCF variant that multiplies each period’s cash flow by the cumulative probability of reaching that period before discounting.<\/li>\n\n\n\n
    • LOE (Loss of Exclusivity):<\/strong> The date, set by the later of patent expiry or regulatory exclusivity, after which generic or biosimilar competition can legally enter.<\/li>\n\n\n\n
    • PTE (Patent Term Extension):<\/strong> Restoration, under 35 U.S.C. \u00a7 156, of up to five years of patent term lost to clinical testing and FDA review, capped at 14 years of total post-approval protection.<\/li>\n\n\n\n
    • BPCIA:<\/strong> The Biologics Price Competition and Innovation Act, which created the FDA biosimilar approval pathway and sets the 12-year biologics exclusivity period.<\/li>\n\n\n\n
    • ANDA:<\/strong> Abbreviated New Drug Application \u2014 the generic drug approval pathway created by the Hatch-Waxman Act.<\/li>\n\n\n\n
    • Paragraph IV Certification:<\/strong> A generic applicant’s assertion that an Orange Book-listed patent is invalid or not infringed, which can trigger patent litigation and an automatic 30-month stay of generic approval.<\/li>\n\n\n\n
    • CVR (Contingent Value Right):<\/strong> A tradable or non-tradable right, issued to target shareholders in an acquisition, that pays out only if specified milestones are achieved.<\/li>\n\n\n\n
    • Real Options Valuation:<\/strong> Application of financial option-pricing theory to value managerial flexibility to continue, expand, delay, or abandon a development program.<\/li>\n<\/ul>\n\n\n\n

      FAQ<\/strong><\/h2>\n\n\n\n

      What discount rate should I use for a Phase II biotech asset?<\/strong>
      Typical practice applies 15\u201320% for early clinical-stage assets, reflecting unproven commercial viability and continued financing risk, rather than the 20\u201325%+ rates used for preclinical assets or the 7\u20139% used for commercial-stage companies.<\/p>\n\n\n\n

      Why does a biologic get a longer regulatory exclusivity period than a small molecule?<\/strong>
      Biologics receive 12 years of exclusivity under the BPCIA versus 5 years of New Chemical Entity exclusivity for small molecules under Hatch-Waxman [66], a gap that also now interacts with the IRA’s negotiation timeline (9 years for small molecules, 13 for biologics), reinforcing biologics’ structural pricing advantage in the later years of the product life cycle.<\/p>\n\n\n\n

      How much does a drug’s price fall after generic entry versus biosimilar entry?<\/strong>
      Small-molecule generics typically trigger an 80\u201390% price collapse within 12 months due to automatic pharmacy substitution. Biosimilars erode more gradually \u2014 Humira’s US net price per prescription fell more than 50% over two full years (2022\u20132024) [59], a materially slower curve.<\/p>\n\n\n\n

      Is the current patent cliff really the largest in the industry’s history?<\/strong>
      By dollar value, most industry estimates put it above the 2011\u20132012 cliff (led by Lipitor), with the prior 2016-era cliff estimated at roughly $100 billion in eroded brand-name sales [17] versus current estimates ranging from $180 billion to $400 billion depending on time window and scope [4][14][15][17].<\/p>\n\n\n\n

      What is a Contingent Value Right and why do so many 2025\u20132026 pharma deals use one?<\/strong>
      A CVR is a payment right tied to future milestones, used to bridge a valuation gap between buyer and seller when they disagree about the odds of a clinical or regulatory event. CVRs featured heavily in H1 2026’s largest biotech deals, including Apellis, Arcellx, Centessa, and Theravance transactions, alongside the Pfizer-Metsera deal [35][45].<\/p>\n\n\n\n

      How is Medicare price negotiation under the IRA actually going to affect a specific drug’s valuation?<\/strong>
      Once a small molecule reaches 9 years post-approval (13 years for a biologic) it becomes eligible for CMS price negotiation, and if selected, a negotiated Maximum Fair Price takes effect roughly two years later \u2014 for example, the second-cycle drugs selected in 2025 have prices effective January 1, 2027, with discounts in some cases exceeding 70% off list price [26][29]. Valuation models for late-stage assets in this window should build in an explicit price step-down rather than smooth continued price growth.<\/p>\n\n\n\n

      Why would a real options model value a risky CNS asset higher than an rNPV model would?<\/strong>
      Because in real options, higher outcome volatility increases value (the upside is uncapped while the downside is capped at the R&D spend to abandon), whereas rNPV simply averages across probability-weighted outcomes and tends to compress a genuinely bimodal, “barbell” outcome distribution toward the middle.<\/p>\n\n\n\n

      What is the practical difference between a VC hurdle rate and an rNPV discount rate?<\/strong>
      A VC hurdle rate (40\u201360%) is a target portfolio-level IRR compensating for illiquidity and high mortality across many bets; an rNPV discount rate is meant to reflect only the asset’s systematic, undiversifiable risk, with technical\/clinical risk handled separately through probability weighting.<\/p>\n\n\n\n

      Does AI-enabled drug discovery actually improve odds of approval, or does it just get more programs into Phase I?<\/strong>
      Early 2026 IQVIA Institute data specifically tested this concern: Phase II success rates for AI-enabled programs at emerging biopharma companies were on par with non-AI-enabled peers rather than lower, which argues against AI simply front-loading weaker programs into the pipeline [1].<\/p>\n\n\n\n

      How is oncology valued differently depending on line of therapy?<\/strong>
      A first-line approval reaches a larger, earlier-stage patient population for a longer treatment duration than a third-line “salvage” approval addressing the same tumor type, which is why line-of-therapy is treated as a primary value driver independent of the underlying molecule’s mechanism.<\/p>\n\n\n\n

      Key Takeaways<\/strong><\/h2>\n\n\n\n
        \n
      • rNPV, not standard DCF, is the dominant framework for clinical-stage assets because it separates asset-specific technical risk (handled via probability weighting of cash flows) from time-value risk (handled via the discount rate) \u2014 conflating the two by using an inflated discount rate is the most common valuation error in the sector.<\/li>\n\n\n\n
      • Phase II remains the highest-attrition stage of development; AI-enabled programs at emerging biopharma companies showed a 75% three-year Phase I success rate in 2026 IQVIA Institute data, with Phase II rates holding steady rather than declining [1].<\/li>\n\n\n\n
      • The IRA’s 9-year (small molecule) versus 13-year (biologic) window before Medicare price negotiation eligibility is now a structural, quantifiable input to terminal-value modeling, not a background policy risk.<\/li>\n\n\n\n
      • Regulatory exclusivity (5 years NCE, 12 years BPCIA, 7 years orphan) combined with a capped Patent Term Extension (max 5 years, 14-year total post-approval cap) typically leaves “effective” patent life at 10\u201314 years, well short of the nominal 20-year term from filing [61][64][66].<\/li>\n\n\n\n
      • Small-molecule generic entry drives 80\u201390% price collapse within 12 months; biosimilar erosion is slower and shallower, as demonstrated by Humira’s documented >50% net-price decline over two full years rather than one [59].<\/li>\n\n\n\n
      • 2025\u20132030 patent-cliff estimates range from $180 billion to $400 billion depending on time window and geographic scope, with roughly 190\u2013200 individual products affected and around 70 of them generating over $1 billion annually [4][14][15][18].<\/li>\n\n\n\n
      • Real options valuation, unlike DCF, treats higher outcome volatility as value-additive, making it the more appropriate tool for genuinely bimodal assets such as disease-modifying CNS therapies.<\/li>\n\n\n\n
      • Contingent Value Rights are now a standard bridge for valuation-gap disputes: the 2025 Pfizer-Metsera deal split roughly three-quarters guaranteed cash to one-quarter contingent milestone value, a real, disclosed data point analysts can anchor comparable deal assumptions to [45].<\/li>\n<\/ul>\n\n\n\n

        References<\/h2>\n\n\n\n
          \n
        1. IQVIA. (2026, May 14). IQVIA Institute’s Global R&D Trends 2026 Report Finds Credible Signal on AI-Enabled Programs<\/em>. https:\/\/www.iqvia.com\/blogs\/2026\/05\/iqvia-institutes-global-r-and-d-trends-2026-report-finds-credible-signal-on-ai-enabled-programs<\/li>\n\n\n\n
        2. IQVIA. (2026). Accelerating drug development from first-in-human to approval | Global Trends in R&D 2026 webinar<\/em>. https:\/\/www.iqvia.com\/events\/2026\/05\/accelerating-drug-development-from-first-in-human-to-approval-global-trends-in-r-and-d-2026-webinar<\/li>\n\n\n\n
        3. GeneOnline News. (2026, May 20). Pharma Faces $236 Billion Patent Cliff by 2030: Key Drugs and Companies at Risk<\/em>. https:\/\/www.geneonline.com\/pharma-faces-236-billion-patent-cliff-by-2030-key-drugs-and-companies-at-risk\/<\/li>\n\n\n\n
        4. Manufacturing Chemist. (2025, November 10). Pfizer clinches $10bn deal to acquire weight-loss biotech Metsera after bidding war with Novo Nordisk<\/em>. https:\/\/manufacturingchemist.com\/pfizer-10bn-acquire-weight-loss-metsera-novo-nordisk<\/li>\n\n\n\n
        5. Foley & Lardner. (2025, September). Will the Next Patent Cliff Further Spur M&A Activity and What Does That Mean for Companies Right Now?<\/em> https:\/\/www.foley.com\/insights\/publications\/2025\/09\/patent-cliff-ma-activity-for-companies-right-now\/<\/li>\n\n\n\n
        6. Drug Discovery News. (2026, February 24). Blockbuster drugs face a massive patent cliff in 2026<\/em>. https:\/\/www.drugdiscoverynews.com\/blockbuster-drugs-face-a-massive-patent-cliff-in-2026-17019<\/li>\n\n\n\n
        7. DeepCeutix Strategic Briefings. (2026, February 2). $300 Billion in Pharma Revenue Loses Patent Protection by 2030<\/em>. https:\/\/deepceutix.com\/insights\/patent-cliff-reformulation<\/li>\n\n\n\n
        8. BS Capital Markets. (2026). Patent Cliffs and the New Pharma M&A Cycle<\/em>. https:\/\/www.bscapitalmarkets.com\/patent-cliffs-and-the-new-pharma-ma-cycle.html<\/li>\n\n\n\n
        9. DrugPatentWatch. (2026, February 16). The Drug Patent Cliff Portfolio: A Strategic Guide to Identifying and Investing in Companies Facing Major Expiries<\/em>. https:\/\/www.drugpatentwatch.com\/blog\/the-drug-patent-cliff-portfolio-a-strategic-guide-to-identifying-and-investing-in-companies-facing-major-expiries\/<\/li>\n\n\n\n
        10. GoodRx. (2026, May 1). What Medicare Drug Price Negotiation Means for You<\/em>. https:\/\/www.goodrx.com\/insurance\/medicare\/drug-price-negotiation<\/li>\n\n\n\n
        11. CMS. Selected Drugs and Negotiated Prices<\/em>. https:\/\/www.cms.gov\/initiatives\/medicare-prescription-drug-affordability\/overview\/medicare-drug-price-negotiation-program\/selected-drugs-negotiated-prices<\/li>\n\n\n\n
        12. The Modern Medicare Agency. Medicare’s Negotiated Drug Prices: What the IRA Actually Changed for 2026 and 2027<\/em>. https:\/\/www.paulbinsurance.com\/medicares-negotiated-drug-prices-what-the-ira-actually-changed-for-2026-and-2027\/<\/li>\n\n\n\n
        13. eMedicare. (2026, March 7). 15 Medicare Drug Negotiations for 2027: Full List<\/em>. https:\/\/www.emedicare.com\/medicare\/medicare-drug-negotiation-15-drugs-2027<\/li>\n\n\n\n
        14. Fierce Pharma. (2026, January 2). Does the Q4 M&A binge foreshadow a boom year for deals in 2026?<\/em> https:\/\/www.fiercepharma.com\/pharma\/2026-forecast-after-surge-ma-q4-will-trend-continue-next-year<\/li>\n\n\n\n
        15. BioBucks. (2026, June 30). Biotech M&A H1 2026 Report \u2014 $149B Across 49 Deals<\/em>. https:\/\/www.biobucks.co\/research-hub\/ma-report-h1-2026<\/li>\n\n\n\n
        16. Life Science Daily. (2026, July 1). Biopharma M&A 2026: Every $1B+ Deal and the Drivers<\/em>. https:\/\/lifesciencedaily.news\/biotech-ma-2026-every-1b-deal-so-far-and-what-is-driving-them\/<\/li>\n\n\n\n
        17. Stock News \/ iTiger. (2025, November 10). Pfizer Clinches $10 Billion Deal for Metsera as Novo Nordisk Withdraws Bid<\/em>. https:\/\/www-web.itiger.com\/news\/1193152910<\/li>\n\n\n\n
        18. DCAT Value Chain Insights. Pfizer Wins Bidding War for Obesity Drug Specialist Metsera<\/em>. https:\/\/www.dcatvci.org\/top-industry-news\/pfizer-wins-bidding-war-for-obesity-drug-specialist-metsera\/<\/li>\n\n\n\n
        19. Fortune. (2025, November 9). Pfizer, Novo Nordisk takeover Metsera obesity<\/em>. https:\/\/fortune.com\/2025\/11\/09\/pfizer-novo-nordisk-takeover-metsera-obesity<\/li>\n\n\n\n
        20. HHS Office of Inspector General. (2025). Most Medicare Part D Plans’ Formularies Included Humira Biosimilars for 2025<\/em>. Report No. OEI-05-23-00520. https:\/\/oig.hhs.gov\/reports\/all\/2025\/most-medicare-part-d-plans-formularies-included-humira-biosimilars-for-2025\/<\/li>\n\n\n\n
        21. Guosen Securities Economic Research Institute. (2026, September 16). Sandoz “Bio100” strategy and the Humira patent cliff review<\/em> [translated]. https:\/\/pdf.dfcfw.com\/pdf\/H3_AP202609161829469497_1.pdf<\/li>\n\n\n\n
        22. GlobalData. Biosimilar market poised for significant growth in the coming years<\/em>. https:\/\/www.globaldata.com\/media\/pharma\/biosimilar-market-poised-for-significant-growth-in-the-coming-years-says-globaldata\/<\/li>\n\n\n\n
        23. BioPharma Dive. Boehringer, GoodRx team up on cheaper Humira biosimilar<\/em>. https:\/\/www.biopharmadive.com\/news\/boehringer-goodrx-Humira-biosimilar-price-cut\/721713\/<\/li>\n\n\n\n
        24. NERA Economic Consulting. (2025, December 22). Humira Biosimilars: A Two-Year Update<\/em>. https:\/\/www.nera.com\/insights\/publications\/2025\/humira-biosimilars–a-two-year-update.html<\/li>\n\n\n\n
        25. Mondaq. (2015, March 4). Patent Term Extension Under 35 U.S.C. \u00a7156<\/em>. https:\/\/webiis08.mondaq.com\/unitedstates\/patent\/379220\/patent-term-extension-under-35-usc-156<\/li>\n\n\n\n
        26. BlueIronIP. How does the 14-year rule affect patent term extension?<\/em> https:\/\/blueironip.com\/?p=17833<\/li>\n\n\n\n
        27. Daeryun Law. Pharmaceutical Patents: How Long Does Drug Exclusivity Last?<\/em> https:\/\/www.daeryunlaw.com\/ja\/practices\/detail\/pharmaceutical-patents<\/li>\n<\/ol>\n\n\n\n

          Source article analyzed for this piece: DrugPatentWatch, “A Definitive Guide to Valuing Pharmaceutical and Biotech Companies,” https:\/\/www.drugpatentwatch.com\/blog\/valuation-of-pharma-companies-5-key-considerations-2\/<\/em><\/p>\n\n\n\n

          <\/p>\n","protected":false},"excerpt":{"rendered":"

          On November 8, 2025, Pfizer agreed to pay up to $10 billion for Metsera, a clinical-stage obesity biotech with no […]<\/p>\n","protected":false},"author":1,"featured_media":39714,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-32915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=32915"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32915\/revisions"}],"predecessor-version":[{"id":39715,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/32915\/revisions\/39715"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39714"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=32915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=32915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=32915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}